| Biomarkers for immunotherapy response in head and neck cancer N Gavrielatou, S Doumas, P Economopoulou, PG Foukas, A Psyrri Cancer treatment reviews 84, 101977, 2020 | 191 | 2020 |
| Patterns of response to immune checkpoint inhibitors in association with genomic and clinical features in patients with head and neck squamous cell carcinoma (HNSCC) P Economopoulou, M Anastasiou, G Papaxoinis, N Spathas, A Spathis, ... Cancers 13 (2), 286, 2021 | 22 | 2021 |
| Discovery of biomarkers of resistance to immune checkpoint blockade in NSCLC using high-plex digital spatial profiling M Moutafi, S Martinez-Morilla, P Divakar, I Vathiotis, N Gavrielatou, ... Journal of Thoracic Oncology 17 (8), 991-1001, 2022 | 18 | 2022 |
| Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer MK Moutafi, M Molero, SM Morilla, J Baena, IA Vathiotis, N Gavrielatou, ... Journal for immunotherapy of cancer 10 (8), 2022 | 18 | 2022 |
| Association of PD-1/PD-L1 co-location with immunotherapy outcomes in non–small cell lung cancer N Gavrielatou, Y Liu, I Vathiotis, J Zugazagoitia, TN Aung, S Shafi, ... Clinical Cancer Research 28 (2), 360-367, 2022 | 17 | 2022 |
| Objective assessment of tumor infiltrating lymphocytes as a prognostic marker in melanoma using machine learning algorithms TN Aung, S Shafi, JS Wilmott, S Nourmohammadi, I Vathiotis, ... EBioMedicine 82, 2022 | 15 | 2022 |
| HER2 aberrations in non-small cell lung cancer: From pathophysiology to targeted therapy IA Vathiotis, A Charpidou, N Gavrielatou, KN Syrigos Pharmaceuticals 14 (12), 1300, 2021 | 12 | 2021 |
| Association of autoimmunity with survival in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab P Economopoulou, I Kotsantis, G Papaxoinis, N Gavrielatou, ... Oral Oncology 111, 105013, 2020 | 11 | 2020 |
| PD-L1 expression scoring: noninterchangeable, noninterpretable, neither, or both N Gavrielatou, S Shafi, P Gaule, DL Rimm JNCI: Journal of the National Cancer Institute 113 (12), 1613-1614, 2021 | 9 | 2021 |
| The role of B cells in head and neck cancer N Gavrielatou, I Vathiotis, P Economopoulou, A Psyrri Cancers 13 (21), 5383, 2021 | 9 | 2021 |
| Development of an immunohistochemical assay for Siglec-15 S Shafi, TN Aung, C Robbins, J Zugazagoitia, I Vathiotis, N Gavrielatou, ... Laboratory Investigation 102 (7), 771-778, 2022 | 8 | 2022 |
| Digital spatial profiling links beta-2-microglobulin expression with immune checkpoint blockade outcomes in head and neck squamous cell carcinoma N Gavrielatou, I Vathiotis, TN Aung, S Shafi, S Burela, AI Fernandez, ... Cancer Research Communications 3 (4), 558-563, 2023 | 7 | 2023 |
| Programmed death-ligand 1 and programmed death-ligand 2 mRNAs measured using closed-system quantitative real-time polymerase chain reaction are associated with outcome and high … AI Fernandez, N Gavrielatou, L McCann, S Shafi, MK Moutafi, ... Journal of Thoracic Oncology 17 (9), 1078-1085, 2022 | 7 | 2022 |
| Next-generation sequencing (NGS) profiling of matched tumor and circulating tumor DNA (ctDNA) in head and neck squamous cell carcinoma (HNSCC) P Economopoulou, A Spathis, I Kotsantis, E Maratou, M Anastasiou, ... Oral Oncology 139, 106358, 2023 | 6 | 2023 |
| Spatial characterization and quantification of CD40 expression across cancer types KM Bates, I Vathiotis, T MacNeil, FS Ahmed, TN Aung, Y Katlinskaya, ... BMC cancer 23 (1), 220, 2023 | 6 | 2023 |
| Quantitative assessment of Siglec-15 expression in lung, breast, head, and neck squamous cell carcinoma and bladder cancer S Shafi, TN Aung, V Xirou, N Gavrielatou, IA Vathiotis, A Fernandez, ... Laboratory Investigation 102 (10), 1143-1149, 2022 | 6 | 2022 |
| Molecular correlates of response to preoperative olaparib alone or with cisplatin or with durvalumab in head and neck squamous cell carcinoma (HNSCC): A Hellenic Cooperative … A Psyrri, G Papaxoinis, N Gavrielatou, M Gkotzamanidou, ... Journal of Clinical Oncology 38 (15_suppl), 6556-6556, 2020 | 6 | 2020 |
| Blood-based testing of mutations in patients with head and neck squamous cell carcinoma (HNSCC) using highly sensitive SafeSEQ technology F Fostira, P Oikonomopoulou, A Kladi, D Edelstein, K Stieler, D Heim, ... Annals of Oncology 30, v469, 2019 | 6 | 2019 |
| Immune checkpoint blockade in hormone receptor-positive breast cancer: resistance mechanisms and future perspectives IA Vathiotis, I Trontzas, N Gavrielatou, G Gomatou, NK Syrigos, ... Clinical Breast Cancer 22 (7), 642-649, 2022 | 3 | 2022 |
| Clinical implications of hyperprogression with immune checkpoint inhibitors in patients with head and neck squamous cell carcinoma (HNSCC). P Economopoulou, NS Spathas, G Papaxoinis, M Anastasiou, ... Journal of Clinical Oncology 37 (15_suppl), 6034-6034, 2019 | 3 | 2019 |
